Postsurgical neuropathic pain: lidocaine 700 mg medicated plaster or oral treatments in clinical practice.
Michael A ÜberallIrmgard BöslEls HollandersIngo SabatschusMariëlle EerdekensPublished in: Pain management (2022)
Aim: To compare the effectiveness and tolerability of the lidocaine 700 mg medicated plaster (LMP) and oral first-line medications (OM) for the treatment of postsurgical neuropathic pain (PSNP) in routine clinical practice. Patients & methods: Data from a noninterventional, retrospective 24-week cohort study in patients with localized peripheral NP refractory to at least one recommended OM using anonymized German Pain eRegistry data were retrieved. A subgroup analysis was conducted on 531 datasets of PSNP patients. Results: Pain relief, improvements in pain-related impairments of daily living and quality of life, and tolerability were significantly greater under LMP than under OM (p < 0.001 for all parameters). Conclusion: These real-world data show the effectiveness and good tolerability of LMP for PSNP treatment in routine clinical practice.
Keyphrases
- neuropathic pain
- clinical practice
- spinal cord
- spinal cord injury
- chronic pain
- end stage renal disease
- epstein barr virus
- ejection fraction
- newly diagnosed
- electronic health record
- randomized controlled trial
- open label
- systematic review
- pain management
- prognostic factors
- clinical trial
- double blind
- data analysis
- artificial intelligence
- combination therapy
- postoperative pain